|
甲基丙烯酸羟丙酯 (HPMA)
|
H109880-10L
|
≥97%, 含0.02% 4-methoxyphenol 稳定剂 |
27813-02-1 |
10L
|
¥ 1308.9
|
现货 |
|
0 |
阿拉丁 |
|
GW 627368,EP4受体竞争性拮抗剂
|
G288949-50mg
|
Moligand™, ≥98%(HPLC) |
439288-66-1 |
50mg
|
¥ 878.9
|
现货 |
|
0 |
阿拉丁 |
|
GW 627368,EP4受体竞争性拮抗剂
|
G288949-10mg
|
Moligand™, ≥98%(HPLC) |
439288-66-1 |
10mg
|
¥ 242.9
|
现货 |
|
0 |
阿拉丁 |
|
GSK2018682,S1P1和S1P5激动剂
|
G288907-50mg
|
Moligand™, ≥98%(HPLC) |
1034688-30-6 |
50mg
|
¥ 2938.9
|
现货 |
|
0 |
阿拉丁 |
|
GSK2018682,S1P1和S1P5激动剂
|
G288907-10mg
|
Moligand™, ≥98%(HPLC) |
1034688-30-6 |
10mg
|
¥ 666.9
|
现货 |
|
0 |
阿拉丁 |
|
Grifolic acid,激动剂
|
G288904-1mg
|
Moligand™, ≥98%(HPLC) |
80557-12-6 |
1mg
|
¥ 1669.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
GR 144053 三盐酸盐
|
G288867-50mg
|
≥99%(HPLC) |
1215333-48-4 |
50mg
|
¥ 7560.9
|
现货 |
|
0 |
阿拉丁 |
|
GR 144053 三盐酸盐
|
G288867-10mg
|
≥99%(HPLC) |
1215333-48-4 |
10mg
|
¥ 1865.9
|
现货 |
|
0 |
阿拉丁 |
|
G 5555,的I组PAK抑制剂
|
G288842-50mg
|
≥98%(HPLC) |
1648863-90-4 |
50mg
|
¥ 4299.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
G 5555,的I组PAK抑制剂
|
G288842-10mg
|
≥98%(HPLC) |
1648863-90-4 |
10mg
|
¥ 1599.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
G-36,GPER拮抗剂
|
G288800-50mg
|
Moligand™, ≥99%(HPLC) |
1392487-51-2 |
50mg
|
¥ 4899.9
|
现货 |
|
0 |
阿拉丁 |
|
G-36,GPER拮抗剂
|
G288800-10mg
|
Moligand™, ≥99%(HPLC) |
1392487-51-2 |
10mg
|
¥ 1519.9
|
现货 |
|
0 |
阿拉丁 |
|
GlyH 101,依赖电压的可逆CFTR氯离子通道阻滞剂
|
G288753-50mg
|
Moligand™, ≥98%, sum of trans and cis |
328541-79-3 |
50mg
|
¥ 2380.9
|
现货 |
|
0 |
阿拉丁 |
|
GlyH 101,依赖电压的可逆CFTR氯离子通道阻滞剂
|
G288753-10mg
|
Moligand™, ≥98%, sum of trans and cis |
328541-79-3 |
10mg
|
¥ 590.9
|
现货 |
|
0 |
阿拉丁 |
|
GNE 9278,NMDA受体的正变构调节剂
|
G288710-50mg
|
≥98%(HPLC) |
901230-11-3 |
50mg
|
¥ 9713.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
GNE 9278,NMDA受体的正变构调节剂
|
G288710-10mg
|
≥98%(HPLC) |
901230-11-3 |
10mg
|
¥ 2318.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
GSK2801,BAZ2A和BAZ2B抑制剂
|
G288683-10mg
|
Moligand™, ≥98%(HPLC) |
1619994-68-1 |
10mg
|
¥ 218.9
|
现货 |
|
0 |
阿拉丁 |
|
GRK2i TFA 盐
|
G288679-1mg
|
≥98% |
148505-03-7 |
1mg
|
¥ 1699.9
|
现货 |
|
0 |
阿拉丁 |
|
GLPG 0187,有效的αv整联蛋白抑制剂
|
G288570-50mg
|
≥97%(HPLC) |
1320346-97-1 |
50mg
|
¥ 6487.9
|
现货 |
|
0 |
阿拉丁 |
|
GLPG 0187,有效的αv整联蛋白抑制剂
|
G288570-10mg
|
≥97%(HPLC) |
1320346-97-1 |
10mg
|
¥ 1852.9
|
现货 |
|
0 |
阿拉丁 |
|
GSK2033,LXR拮抗剂
|
G288522-50mg
|
Moligand™, ≥96% |
1221277-90-2 |
50mg
|
¥ 5167.9
|
现货 |
|
0 |
阿拉丁 |
|
GSK2033,LXR拮抗剂
|
G288522-10mg
|
Moligand™, ≥96% |
1221277-90-2 |
10mg
|
¥ 1420.9
|
现货 |
|
0 |
阿拉丁 |
|
GSK264220A,内皮脂酶和脂蛋白脂酶抑制剂
|
G288505-50mg
|
Moligand™, ≥98%(HPLC) |
685506-42-7 |
50mg
|
¥ 7901.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
GSK264220A,内皮脂酶和脂蛋白脂酶抑制剂
|
G288505-10mg
|
Moligand™, ≥98%(HPLC) |
685506-42-7 |
10mg
|
¥ 1875.9
|
期货,请咨询 |
|
0 |
阿拉丁 |